Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...

The sleep aid Ambien could be allowing toxic proteins to pollute the brain, potentially increasing a person’s risk of ...

Bristol Myers Squibb CEO Chris Boerner described Cobenefy, a new drug to treat schizophrenia and may also help with bipolar ...

(Reuters) -AbbVie has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical's unit for ...

Statins: For statins, the side effects can be surprising. Some people taking these medications have been found to gain weight ...

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center have identified a ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

A THOROUGH investigation looms over the Philippine National Police (PNP) confiscation of illegal drugs since 2016 ahead of ...

Diabetes, a chronic condition that affects millions of people, may have a connection with Alzheimer's disease. Unofficially ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...